His primary areas of investigation include Renal cell carcinoma, Carcinoma, Internal medicine, Surgery and Nephrectomy. His Renal cell carcinoma research is multidisciplinary, relying on both Kidney, Radiology and Kidney disease. The Carcinoma study combines topics in areas such as Adenocarcinoma, Disease, Stage, Primary tumor and Immunotherapy.
Arie S. Belldegrun has included themes like Gastroenterology, Endocrinology and Oncology in his Internal medicine study. His work carried out in the field of Surgery brings together such families of science as Prostate, Epidemiology and Intensive care medicine. His Nephrectomy research is multidisciplinary, incorporating perspectives in Survival rate, Predictive value of tests, Retrospective cohort study, Proportional hazards model and Univariate analysis.
Arie S. Belldegrun mainly investigates Renal cell carcinoma, Internal medicine, Oncology, Pathology and Nephrectomy. The study incorporates disciplines such as Carcinoma, Surgery, Kidney disease and Immunotherapy in addition to Renal cell carcinoma. His studies in Carcinoma integrate themes in fields like Survival rate, Survival analysis, Performance status and Adenocarcinoma.
All of his Internal medicine and Nephrology, Cancer, Prostate cancer, Clear cell renal cell carcinoma and Stage investigations are sub-components of the entire Internal medicine study. Arie S. Belldegrun combines subjects such as Metastasis, Clinical trial and Disease with his study of Oncology. Arie S. Belldegrun has researched Nephrectomy in several fields, including Proportional hazards model and Urology.
The scientist’s investigation covers issues in Internal medicine, Renal cell carcinoma, Oncology, Clear cell renal cell carcinoma and Surgery. His Renal cell carcinoma research integrates issues from Carcinoma, Proportional hazards model, Nephrectomy and Immunotherapy. His Carcinoma research is multidisciplinary, relying on both Kidney and Performance status.
His work carried out in the field of Nephrectomy brings together such families of science as Retrospective cohort study and Urology. His Oncology study combines topics from a wide range of disciplines, such as Adjuvant therapy and Cohort. Arie S. Belldegrun interconnects Body mass index, Overweight and Placebo in the investigation of issues within Surgery.
Arie S. Belldegrun mainly investigates Renal cell carcinoma, Internal medicine, Carcinoma, Oncology and Pathology. The various areas that Arie S. Belldegrun examines in his Renal cell carcinoma study include Immunology, Proportional hazards model, Nephrectomy, Biomarker and Immunotherapy. Internal medicine is frequently linked to Surgery in his study.
Kidney cancer is the focus of his Carcinoma research. His research in Oncology intersects with topics in Stage, Gynecology and Adjuvant therapy. His Clear cell renal cell carcinoma study in the realm of Pathology connects with subjects such as Grading.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
Allan J. Pantuck;Amnon Zisman;Arie S. Belldegrun.
The Journal of Urology (2001)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.
Nicolette K Janzen;Hyung L Kim;Robert A Figlin;Arie S Belldegrun.
Urologic Clinics of North America (2003)
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
Amnon Zisman;Allan J. Pantuck;Fredrick Dorey;Jonathan W. Said.
Journal of Clinical Oncology (2001)
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo.
Journal of Clinical Oncology (2005)
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy
Matthew H.T. Bui;David Seligson;Ken ryu Han;Allan J. Pantuck.
Clinical Cancer Research (2003)
SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE
Jean-Jacques Patard;Oleg Shvarts;John S. Lam;Allan J. Pantuck.
The Journal of Urology (2004)
Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma
Amnon Zisman;Allan J. Pantuck;Jeffery Wieder;Debby H. Chao.
Journal of Clinical Oncology (2002)
Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma
Matthew H. T. Bui;David Seligson;Ken-ryu Han;Allan J. Pantuck.
American Association for Cancer Research (2003)
Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.
Ke-Hung Tsui;Oleg Shvarts;Robert B. Smith;Robert A. Figlin.
The Journal of Urology (2000)
Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer
Allan J. Pantuck;John T. Leppert;Nazy Zomorodian;William Aronson.
Clinical Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: